## Squamous Cell Carcinoma of Lung: First-Line Chemotherapy **Key Point:** Cisplatin-based doublet chemotherapy remains the gold standard for locally advanced squamous cell carcinoma (SCC) of the lung in chemotherapy-naive patients without targetable mutations. ### Rationale for Cisplatin + Gemcitabine **High-Yield:** Cisplatin + gemcitabine is the preferred regimen for SCC lung because: - Cisplatin is a platinum agent with proven efficacy in SCC histology - Gemcitabine is a nucleoside analog with synergistic activity - This combination has superior response rates and overall survival compared to single-agent therapy - Well-established toxicity profile and supportive care protocols **Clinical Pearl:** Squamous cell carcinoma of the lung arises from metaplasia of the normal columnar respiratory epithelium to stratified squamous epithelium (a consequence of chronic irritation from smoking). Once dysplasia and carcinoma develop, chemotherapy becomes necessary. ### Comparison of Options | Agent/Regimen | Indication | Limitation in SCC | |---|---|---| | Cisplatin + Gemcitabine | First-line SCC, locally advanced | Gold standard; requires adequate renal function | | Pembrolizumab monotherapy | PD-L1 high (≥50%), first-line | Reserved for PD-L1 high tumors; not standard for all SCC | | Erlotinib | EGFR-mutant NSCLC | SCC rarely harbors EGFR mutations; not first-line | | Bevacizumab + Paclitaxel | Non-squamous NSCLC | Bevacizumab contraindicated in SCC (risk of hemoptysis) | **Warning:** Bevacizumab is contraindicated in squamous cell lung cancer due to increased risk of pulmonary hemorrhage and hemoptysis. **Mnemonic:** **SCCP** = **S**quamous **C**ell → **C**isplatin + **P**latinum-based doublet (Gemcitabine/Pemetrexed).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.